RESEARCH PAPER
Time to antiretroviral therapy initiation
in HIV-positive patients with opportunistic infections/AIDS-defining illness in Southern Thailand: a prospective cohort study
1
Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hat Yai, Songkhla, Thailand
2
Division of Clinical Pharmacy, Department of Pharmaceutical Care, School of Pharmaceutical Sciences, University of Phayao, Phayao, Thailand
Submission date: 2022-05-24
Final revision date: 2022-07-10
Acceptance date: 2022-07-10
Online publication date: 2024-04-11
Corresponding author
Chanadda Wuttikul
Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hat Yai, Songkhla, Thailand
Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hat Yai, Songkhla, Thailand
HIV & AIDS Review 2024;23(3):226-232
KEYWORDS
antiretroviral therapyopportunistic infectionsAIDS-defining illnessesco-infectiontime to antiretroviral therapy initiation
TOPICS
ABSTRACT
Introduction:
Rapid antiretroviral therapy (ART) initiation is recommended for all people living with human immunodeficiency virus (HIV). Time to ART initiation in individual patients depends on several factors. The study objectives were to investigate the time to ART initiation in HIV-positive patients with opportunistic infections/AIDS-defining illnesses (OIs/ADI), and associated factors.
Material and methods:
A prospective cohort study was performed among ART-naïve HIV patients with OIs/ADI. Time to ART initiation was defined as the time from being diagnosed with OIs/ADI to ART initiation.
Results:
A total of 253 patients were included. The three most common OIs were tuberculosis (36.8%), Pneumocystis jirovecii pneumonia (26.1%), and candidiasis (19.0%). 39.9% of patients learned about their HIV-serostatus after OIs/ADI diagnosis. The median time from OIs/ADI diagnosis to ART initiation was 38 days (IQR, 23-71). From Cox regression model, the factor independently associated with a shorter waiting time to ART initiation was continuous engagement in HIV care (aHR = 2.42; 95% CI: 1.70-3.45). On the other hand, the factors associated with a longer time to ART initiation were tuberculosis co-infection (aHR = 0.52; 95% CI: 0.36-0.75), HIV diagnosis after OIs/ADI (aHR = 0.42; 95% CI: 0.30-0.57), viral hepatitis B/C co-infection (aHR = 0.59; 95% CI: 0.39-0.89), seeking care in general hospital and community hospital (aHR = 0.67; 95% CI: 0.49-0.93, and aHR = 0.62; 95% CI: 0.44-0.86, respectively), having more than one hospital admission in the past six months (aHR = 0.60; 95% CI: 0.44-0.81), and history of missed appointments (aHR = 0.62; 95% CI: 0.42-0.91).
Conclusions:
To achieve maximal benefits of ART, strategies to improve HIV awareness, continuous care engagement, and timely ART initiation are required.
Rapid antiretroviral therapy (ART) initiation is recommended for all people living with human immunodeficiency virus (HIV). Time to ART initiation in individual patients depends on several factors. The study objectives were to investigate the time to ART initiation in HIV-positive patients with opportunistic infections/AIDS-defining illnesses (OIs/ADI), and associated factors.
Material and methods:
A prospective cohort study was performed among ART-naïve HIV patients with OIs/ADI. Time to ART initiation was defined as the time from being diagnosed with OIs/ADI to ART initiation.
Results:
A total of 253 patients were included. The three most common OIs were tuberculosis (36.8%), Pneumocystis jirovecii pneumonia (26.1%), and candidiasis (19.0%). 39.9% of patients learned about their HIV-serostatus after OIs/ADI diagnosis. The median time from OIs/ADI diagnosis to ART initiation was 38 days (IQR, 23-71). From Cox regression model, the factor independently associated with a shorter waiting time to ART initiation was continuous engagement in HIV care (aHR = 2.42; 95% CI: 1.70-3.45). On the other hand, the factors associated with a longer time to ART initiation were tuberculosis co-infection (aHR = 0.52; 95% CI: 0.36-0.75), HIV diagnosis after OIs/ADI (aHR = 0.42; 95% CI: 0.30-0.57), viral hepatitis B/C co-infection (aHR = 0.59; 95% CI: 0.39-0.89), seeking care in general hospital and community hospital (aHR = 0.67; 95% CI: 0.49-0.93, and aHR = 0.62; 95% CI: 0.44-0.86, respectively), having more than one hospital admission in the past six months (aHR = 0.60; 95% CI: 0.44-0.81), and history of missed appointments (aHR = 0.62; 95% CI: 0.42-0.91).
Conclusions:
To achieve maximal benefits of ART, strategies to improve HIV awareness, continuous care engagement, and timely ART initiation are required.
REFERENCES (30)
1.
Department of Health and Human Services. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV; 2021. Available from: https://clinicalinfo.hiv.gov/e... (Accessed: 06.08.2021).
2.
World Health Organization. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach Geneva; 2021. Available from: https://www.who.int/publicatio... (Accessed: 08.2021).
3.
The Joint United Nations Programme on HIV/AIDS. Global HIV & AIDS satatistics-fact sheet; 2021. Available from: https://www.unaids.org/en/reso... (Accessed: 27.05.2022).
4.
IeDEA and COHERE Cohort Collaborations. Global trends in CD4 cell count at the start of antiretroviral therapy: collaborative study of treatment programs. Clin Infect Dis 2018; 66: 893-903.
5.
Ribeiro LCS, Freitas MIF, Tupinambás U, Lana FCF. Late diagnosis of human immunodeficiency virus infection and associated factors. Rev Lat Am Enfermagem 2020; 28: e3342. DOI: 10.1590/1518-8345.4072.3342.
6.
Xu J, Sönnerborg A, Gao L, Wang P, Bouey JZH, Cheng F. Delayed treatment for people living with HIV in China, 2004-2016: an analysis of an observational cohort. Int J Environ Res Public Health 2020; 17: 1809. DOI: 10.3390/ijerph17051809.
7.
Lawn SD, Toeroek ME, Wood R. Optimum time to start antiretroviral therapy during HIV-associated opportunistic infections. Curr Opin Infect Dis 2011; 24: 34-42.
8.
Wajanga BM, Peck RN, Kalluvya S, Fitzgerald DW, Smart LR, Downs JA. Healthcare worker perceived barriers to early initiation of antiretroviral and tuberculosis therapy among Tanzanian inpatients. PLoS One 2014; 9: e87584. DOI: 10.1371/journal.pone.0087584.
9.
Beer L, Valverde EE, Raiford JL, Weiser J, White BL, Skarbinski J. Clinician perspectives on delaying initiation of antiretroviral therapy for clinically eligible HIV-infected patients. J Int Assoc Prov AIDS Care 2015; 14: 245-254.
10.
Deconinck L, Yazdanpanah Y, Gilson RJ, Melliez H, Viget N, Joly V, et al. Time to initiation of antiretroviral therapy in HIV-infected patients diagnosed with an opportunistic disease: a cohort study. HIV Med 2015; 16: 219-229.
11.
Cingolani A, Cozzi-Lepri A, Ammassari A, Mussini C, Ursitti MA, Caramello P, et al. Timing of antiretroviral therapy initiation after a first AIDS-defining event: temporal changes in clinical attitudes in the ICONA cohort. PLoS One 2014; 9: e89861. doi: 10.1371/journal.pone.0089861.
12.
Manzardo C, Esteve A, Ortega N, Podzamczer D, Murillas J, Segura F, et al. Optimal timing for initiation of highly active antiretroviral therapy in treatment-naïve human immunodeficiency virus-1-infected individuals presenting with AIDS-defining diseases: the experience of the PISCIS cohort. Clin Microbiol Infect 2013; 19: 646-653.
13.
Miro JM, Manzardo C, Mussini C, Johnson M, d'Arminio Monforte A, Antinori A, et al. Survival outcomes and effect of early vs. deferred cART among HIV-infected patients diagnosed at the time of an AIDS-defining event: a cohort analysis. PLoS One 2011; 6: e26009. DOI: 10.1371/journal.pone.0026009.
14.
Crabtree-Ramirez B, Caro-Vega Y, Shepherd BE, Grinsztejn B, Wolff M, Cortes CP, et al. Time to HAART initiation after diagnosis and treatment of opportunistic infections in patients with AIDS in LatinAmerica. PLoS One 2016; 11: e0153921. DOI: 10.1371/journal.pone.0153921.
15.
Tweya H, Ben-Smith A, Kalulu M, Jahn A, Ng'ambi W, Mkandawire E, et al. Timing of antiretroviral therapy and regimen for HIV-infected patients with tuberculosis: the effect of revised HIV guidelines in Malawi. BMC Public Health 2014; 14: 183. DOI: 10.1186/1471-2458-14-183.
16.
Choun K, Pe R, Thai S, Lorent N, Lynen L, van Griensven J. Timing of antiretroviral therapy in Cambodian hospital after diagnosis of tuberculosis: impact of revised WHO guidelines. Bull World Health Organ 2013; 91: 195-206.
17.
Thi AM, Shewade HD, Kyaw NT, Oo MM, Aung TK, Aung ST, et al. Timing of antiretroviral therapy and TB treatment outcomes in patients with TB-HIV in Myanmar. Public Health Action 2016; 6: 111-117.
18.
Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41(Rr-17): 1-19.
19.
Robertson M, Laraque F, Mavronicolas H, Braunstein S, Torian L. Linkage and retention in care and the time to HIV viral suppression and viral rebound – New York City. AIDS Care 2015; 27: 260-267.
20.
Shah M, Risher K, Berry SA, Dowdy DW. The epidemiologic and economic impact of improving HIV testing, linkage, and retention in care in the United States. Clin Infect Dis 2016; 62: 220-229.
21.
Hoffman S, Leu CS, Ramjee G, Blanchard K, Gandhi AD, O'Sullivan L, et al. Linkage to care following an HIV diagnosis in three public sector clinics in eThekwini (Durban), South Africa: findings from a prospective cohort study. AIDS Behav 2020; 24: 1181-1196.
22.
Sanga ES, Mukumbang FC, Mushi AK, Lerebo W, Zarowsky C. Understanding factors influencing linkage to HIV care in a rural setting, Mbeya, Tanzania: qualitative findings of a mixed methods study. BMC Public Health 2019; 19: 383. DOI: 10.1186/s12889-019-6691-7.
23.
Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 2015; 373: 795-807.
24.
Adewumi OM, Odaibo GN, Olaleye OD. Baseline CD4 T cell level predicts recovery rate after initiation of ART in HIV infected Nigerians. J Immunoassay Immunochem 2016; 37: 109-118.
25.
Kalichman SC, Cherry C, Kalichman MO, Washington C, Grebler T, Hoyt G, et al. Sexual behaviors and transmission risks among people living with HIV: beliefs, perceptions, and challenges to using treatments as prevention. Arch Sex Behav 2016; 45: 1421-1430.
26.
Smith RM, Carrico AW, Montandon M, Kwena Z, Bailey R, Bukusi EA, et al. Attitudes and beliefs about anti-retroviral therapy are associated with high risk sexual behaviors among the general population of Kisumu, Kenya. AIDS Care 2011; 23: 1668-1675.
27.
Letamo G, Keetile M, Navaneetham K. The impact of HIV antiretroviral treatment perception on risky sexual behaviour in Botswana: a short report. AIDS Care 2017; 29: 1589-1593.
28.
Thai Ministry of Public Health. Thailand national guidelines on HIV/AIDS diagnosis, treatment and prevention 2020/2021. Aksorn graphic and design. Bangkok; 2020, p. 29-96.
29.
Mgbere O, Rodriguez-Barradas M, Vigil KJ, McNeese M, Tabassam F, Barahmani N, et al. Systemic delays in the initiation of antiretroviral therapy for clinically eligible HIV-infected patients in Houston, Texas: the providers' report card. J Int Assoc Provid AIDS Care 2018; 17: 2325958218774042. DOI: 10.1177/2325958218774042.
30.
Giordano TP, White AC Jr, Sajja P, Graviss EA, Arduino RC, Adu-Oppong A, et al. Factors associated with the use of highly active antiretroviral therapy in patients newly entering care in an urban clinic. J Acquir Immune Defic Syndr 2003; 32: 399-405.
Share
RELATED ARTICLE
| eISSN: | 1732-2707 |
| ISSN: | 1730-1270 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
